Article
The panelists offer their closing remarks regarding immuno-oncology's promises and challenges.
The panelists offer their closing remarks regarding immuno-oncology’s promises and challenges.
Jianda Yuan, MD, PhD, explains why this is an exciting time for immunotherapy, and Kimberly Shafer-Weaver, PhD, added that discussing immuno-oncology early on is important so that the best decisions can be made for not only patients, but also the payers.
“Sometimes, it is tempting, I think, to get discouraged that the innovations that we are seeing are going to come at a price tag that we cannot afford,” Michael Kolodziej, MD, added in conclusion. “I think that is a mistake. I think that what we should be focused on is really finding out how much these innovations truly add to what we are doing now and who benefits the most.”
Overhauling Quality Measurement in the US: Measure What Matters